Hologic (NASDAQ:HOLX) PT Raised to $90.00 at Mizuho

Hologic (NASDAQ:HOLXFree Report) had its price objective raised by Mizuho from $85.00 to $90.00 in a research note published on Friday morning, Benzinga reports. The firm currently has an outperform rating on the medical equipment provider’s stock.

Other analysts also recently issued research reports about the stock. Royal Bank of Canada reaffirmed a sector perform rating and set a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Evercore ISI lifted their price target on shares of Hologic from $78.00 to $82.00 and gave the company an in-line rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. increased their price target on Hologic from $91.00 to $95.00 and gave the stock an overweight rating in a research note on Tuesday, July 30th. StockNews.com lowered shares of Hologic from a strong-buy rating to a buy rating in a report on Friday, September 27th. Finally, Citigroup downgraded shares of Hologic from a buy rating to a neutral rating and reduced their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $87.27.

Get Our Latest Stock Analysis on Hologic

Hologic Stock Down 0.4 %

HOLX stock opened at $79.88 on Friday. The company has a market capitalization of $18.64 billion, a price-to-earnings ratio of 40.76, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. The business’s 50 day moving average price is $81.28 and its two-hundred day moving average price is $77.48. Hologic has a fifty-two week low of $64.02 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Hologic (NASDAQ:HOLXGet Free Report) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the business earned $0.93 EPS. Hologic’s revenue was up 2.7% compared to the same quarter last year. As a group, analysts forecast that Hologic will post 4.09 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hologic

Several institutional investors and hedge funds have recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in Hologic in the 2nd quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic during the 1st quarter worth approximately $37,000. Sunbelt Securities Inc. purchased a new stake in Hologic in the 2nd quarter worth $37,000. Cranbrook Wealth Management LLC acquired a new position in Hologic during the second quarter worth $47,000. Finally, Mather Group LLC. purchased a new position in Hologic during the first quarter valued at $48,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

About Hologic

(Get Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Articles

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.